BACKGROUND: Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). METHODS: Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. RESULTS: HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.20, respectively). HPV16 E6 antibodies were present in 30.2% of oropharyngeal case subjects and only 0.8% of control subjects (OR = 132.0, 95% CI = 65.29 to 266.86). Combined seropositivity to HPV16 E6 and E7 was rare (n = 1 of 1425 control subjects). An agreement of 67% was observed between HPV16 E6 serology and the corresponding presence of an HPV-related cancer: four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6 antibody positive. An HPV16 independent association was observed for HPV18 and oropharyngeal cancer (OR = 8.14, 95% CI = 2.21 to 29.99 for HPV18 E6 seropositivity) and HPV6 and laryngeal cancer (OR = 3.25, 95% CI = 1.46 to 7.24 for HPV6 E7 seropositivity). CONCLUSIONS: These results confirm an important role for HPV16 infection in oropharyngeal cancer. HPV16 E6 antibodies are strongly associated with HPV16-related oropharyngeal cancers. Continuing efforts are needed to consider both HPV serology and p16 staining as biomarkers relevant to the etiology and natural history of HPV16-related oropharyngeal tumors. These results also support a marginal role for HPV18 in oropharyngeal cancer and HPV6 in laryngeal cancer.
BACKGROUND:Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). METHODS: Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. RESULTS:HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.20, respectively). HPV16 E6 antibodies were present in 30.2% of oropharyngeal case subjects and only 0.8% of control subjects (OR = 132.0, 95% CI = 65.29 to 266.86). Combined seropositivity to HPV16 E6 and E7 was rare (n = 1 of 1425 control subjects). An agreement of 67% was observed between HPV16 E6 serology and the corresponding presence of an HPV-related cancer: four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6 antibody positive. An HPV16 independent association was observed for HPV18 and oropharyngeal cancer (OR = 8.14, 95% CI = 2.21 to 29.99 for HPV18 E6 seropositivity) and HPV6 and laryngeal cancer (OR = 3.25, 95% CI = 1.46 to 7.24 for HPV6 E7 seropositivity). CONCLUSIONS: These results confirm an important role for HPV16 infection in oropharyngeal cancer. HPV16 E6 antibodies are strongly associated with HPV16-related oropharyngeal cancers. Continuing efforts are needed to consider both HPV serology and p16 staining as biomarkers relevant to the etiology and natural history of HPV16-related oropharyngeal tumors. These results also support a marginal role for HPV18 in oropharyngeal cancer and HPV6 in laryngeal cancer.
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Krystle A Lang Kuhs; Aimée R Kreimer; Sumita Trivedi; Dana Holzinger; Michael Pawlita; Ruth M Pfeiffer; Sandra P Gibson; Nicole C Schmitt; Allan Hildesheim; Tim Waterboer; Robert L Ferris Journal: Cancer Date: 2017-09-26 Impact factor: 6.860
Authors: Charles A Riley; Eric L Wu; Mei-Chin Hsieh; Michael J Marino; Xiao-Cheng Wu; Edward D McCoul Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-02-01 Impact factor: 6.223
Authors: Krystle A Lang Kuhs; Devasena Anantharaman; Tim Waterboer; Mattias Johansson; Paul Brennan; Angelika Michel; Martina Willhauck-Fleckenstein; Mark P Purdue; Ivana Holcátová; Wolfgang Ahrens; Pagona Lagiou; Jerry Polesel; Lorenzo Simonato; Franco Merletti; Claire M Healy; Kristina Kjaerheim; David I Conway; Tatiana V Macfarlane; Peter Thomson; Xavier Castellsagué; Ariana Znaor; Amanda Black; Wen-Yi Huang; Vittorio Krogh; Antonia Trichopoulou; H B As Bueno-de-Mesquita; Françoise Clavel-Chapelon; Elisabete Weiderpass; Johanna Ekström; Elio Riboli; Anne Tjønneland; María-José Sánchez; Ruth C Travis; Allan Hildesheim; Michael Pawlita; Aimée R Kreimer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01-26 Impact factor: 4.254
Authors: Dominique S Michaud; Scott M Langevin; Melissa Eliot; Heather H Nelson; Michael Pawlita; Michael D McClean; Karl T Kelsey Journal: Int J Cancer Date: 2014-03-07 Impact factor: 7.396
Authors: Devasena Anantharaman; David C Muller; Pagona Lagiou; Wolfgang Ahrens; Ivana Holcátová; Franco Merletti; Kristina Kjærheim; Jerry Polesel; Lorenzo Simonato; Cristina Canova; Xavier Castellsague; Tatiana V Macfarlane; Ariana Znaor; Peter Thomson; Max Robinson; David I Conway; Claire M Healy; Anne Tjønneland; Ulla Westin; Johanna Ekström; Jenny Chang-Claude; Rudolf Kaaks; Kim Overvad; Dagmar Drogan; Göran Hallmans; Göran Laurell; H B Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Nerea Larrañaga; Ruth C Travis; Domenico Palli; Aurelio Barricarte; Antonia Trichopoulou; Saitakis George; Dimitrios Trichopoulos; J Ramón Quirós; Sara Grioni; Carlotta Sacerdote; Carmen Navarro; María-José Sánchez; Rosario Tumino; Gianluca Severi; Marie-Christine Boutron-Ruault; Francoise Clavel-Chapelon; Salvatore Panico; Elisabete Weiderpass; Eiliv Lund; Inger T Gram; Elio Riboli; Michael Pawlita; Tim Waterboer; Aimée R Kreimer; Mattias Johansson; Paul Brennan Journal: Int J Epidemiol Date: 2016-05-19 Impact factor: 7.196